Patient characteristics
| Characteristic . | No. (%) of patients (N = 45) . |
|---|---|
| Age, y | |
| Median | 12.2 |
| Range | 1.3-25.3 |
| Female sex | 22 (48.9) |
| Disease status | |
| Primary refractory | 3 (6.7) |
| First relapse | 15 (33.3) |
| Second relapse | 22 (48.9) |
| ≥Third relapse | 5 (11.1) |
| No. of prior allogeneic transplantations | |
| 0 | 17 (37.8) |
| 1 | 24 (53.3) |
| 2 | 4 (8.9) |
| Time since allogeneic transplantation, mo | |
| Median | 18.3 |
| Range | 4.0-58.6 |
| Disease status at lymphodepletion | |
| M3 | 22 (48.9) |
| M2 | 6 (13.3) |
| M1 | 8 (17.8) |
| MRD− | 7 (15.6) |
| CNS status at lymphodepletion | |
| CNS1 | 34 (79.1) |
| CNS2 | 7 (16.3) |
| CNS3 | 2 (4.7) |
| ALC, cells per µL | |
| Median | 1228 |
| Range | 168-4 488 |
| ABC range, cells per µL | 0-48 407 |
| Characteristic . | No. (%) of patients (N = 45) . |
|---|---|
| Age, y | |
| Median | 12.2 |
| Range | 1.3-25.3 |
| Female sex | 22 (48.9) |
| Disease status | |
| Primary refractory | 3 (6.7) |
| First relapse | 15 (33.3) |
| Second relapse | 22 (48.9) |
| ≥Third relapse | 5 (11.1) |
| No. of prior allogeneic transplantations | |
| 0 | 17 (37.8) |
| 1 | 24 (53.3) |
| 2 | 4 (8.9) |
| Time since allogeneic transplantation, mo | |
| Median | 18.3 |
| Range | 4.0-58.6 |
| Disease status at lymphodepletion | |
| M3 | 22 (48.9) |
| M2 | 6 (13.3) |
| M1 | 8 (17.8) |
| MRD− | 7 (15.6) |
| CNS status at lymphodepletion | |
| CNS1 | 34 (79.1) |
| CNS2 | 7 (16.3) |
| CNS3 | 2 (4.7) |
| ALC, cells per µL | |
| Median | 1228 |
| Range | 168-4 488 |
| ABC range, cells per µL | 0-48 407 |
ABC, absolute blast count; ALC, absolute lymphocyte count.